Skip to main content
Livermore
Livermore
ZHEN

72 Investment Holdings, LLC

SEC CIK
0001832749
Latest filing
Aug 14, 2026

The latest 13F from 72 Investment Holdings, LLC covers Q2 2026 (filed Aug 14, 2026): 5 long positions worth $50.0M. The top 10 holdings make up 100.0% of the portfolio, and the largest is Praxis Precision Medicines, Inc. (PRAX) at 44.2%. Livermore has 22 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
0
Added
0
Reduced
0
Sold out
0

Top 5 holdings

Share of this quarter's portfolio value

  1. PRAXPraxis Precision Medicines, Inc.
    44.2%$22.1MHistory
  2. ANROAlto Neuroscience, Inc.
    35.3%$17.6MHistory
  3. LENZLENZ Therapeutics, Inc.
    11.6%$5.78MHistory
  4. KRROKorro Bio, Inc.
    7.3%$3.65MHistory
  5. CRBUCaribou Biosciences, Inc.
    1.7%$834.4KHistory

Share of portfolio

Each position's share of portfolio value

  1. PRAX44.2%
  2. ANRO35.3%
  3. LENZ11.6%
  4. KRRO7.3%
  5. CRBU1.7%

Biggest buys

New and added positions, by estimated amount bought

None this quarter.

Largest weight increases

New and added positions, by percentage points of the portfolio gained

None this quarter.

Biggest sells

Reduced and sold-out positions, by estimated amount sold

None this quarter.

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

None this quarter.

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$50.0M
+$358.7K (+0.7%) vs. prior quarter
Positions
5
0 vs. prior quarter
Top 10 concentration
100.0%
Top 10 as share of value
Turnover
0.0%
Q2 2026, one quarter
Average holding period
10.7 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $217.5M (Q4 2022)

Q1 2021: $66.1MQ2 2021: $63.5MQ3 2021: $80.1MQ4 2021: $112.7MQ1 2022: $91.4MQ2 2022: $64.7MQ3 2022: $126.2MQ4 2022: $217.5MQ1 2023: $211.2MQ2 2023: $12.8MQ3 2023: $14.9MQ4 2023: $22.5MQ1 2024: $67.1MQ2 2024: $39.8MQ3 2024: $46.5MQ4 2024: $49.1MQ1 2025: $35.6MQ2 2025: $38.3MQ3 2025: $67.9MQ4 2025: $50.6MQ1 2026: $49.6MQ2 2026: $50.0M
Q1 2021Q2 2026
13F filings of 72 Investment Holdings, LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 20265$50.0MPRAXANROLENZvs. Q1 2026SEC
Q1 2026May 15, 20265$49.6MPRAXANROLENZvs. Q4 2025SEC
Q4 2025Feb 17, 20265$50.6MPRAXLENZANROvs. Q3 2025SEC
Q3 2025Nov 14, 20255$67.9MLENZKRROPRAXvs. Q2 2025SEC
Q2 2025Aug 14, 20256$38.3MLENZKRROPRAXvs. Q1 2025SEC
Q1 2025May 15, 20256$35.6MLENZKRROPRAXvs. Q4 2024SEC
Q4 2024Feb 14, 20257$49.1MLENZKRROPRAXvs. Q3 2024SEC
Q3 2024Nov 14, 20247$46.5MLENZKRROANROvs. Q2 2024SEC
Q2 2024Aug 14, 20247$39.8MLENZKRROANROvs. Q1 2024SEC
Q1 2024May 15, 20247$67.1MKRROLENZANROvs. Q4 2023SEC
Q4 2023Feb 14, 20246$22.5MKRROCRBUTRDAvs. Q3 2023SEC
Q3 2023Nov 14, 20235$14.9MTRDACRBUTSBXvs. Q2 2023SEC
Q2 2023Aug 14, 20234$12.8MTRDACRBUOMGAvs. Q1 2023SEC
Q1 2023May 15, 20235$211.2MRXDXTRDACRBUvs. Q4 2022SEC
Q4 2022Feb 14, 20235$217.5MRXDXTRDACRBUvs. Q3 2022SEC
Q3 2022Nov 14, 20225$126.2MRXDXTRDACRBUvs. Q2 2022SEC
Q2 2022Aug 15, 20225$64.7MRXDXTRDACRBUvs. Q1 2022SEC
Q1 2022May 16, 20226$91.4MRXDXPRAXTRDAvs. Q4 2021SEC
Q4 2021Feb 14, 20226$112.7MRXDXPRAXTRDAvs. Q3 2021SEC
Q3 2021Nov 15, 20214$80.1MRXDXPRAXCRBUvs. Q2 2021SEC
Q2 2021Aug 16, 20212$63.5MRXDXPRAXvs. Q1 2021SEC
Q1 2021May 17, 20212$66.1MRXDXPRAX–SEC

13D and 13G filings

Companies where 72 Investment Holdings, LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

72 Investment Holdings, LLC does not currently report owning 5% or more of any company.

Latest filings

16 filings on file made by 72 Investment Holdings, LLC or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by 72 Investment Holdings, LLC
CompanyFiled (ET)FilerFormStakeChangeEvent dateFiling
KRROKorro Bio, Inc.May 15, 20264:30 PM ETPoint72 Asset Management, L.P.and 5 others13G/A1.90%276.8K shares−3.80 ppfrom 5.70%Below 5%Mar 31, 2026SEC
PRAXPraxis Precision Medicines, Inc.May 15, 20264:15 PM ETPoint72 Asset Management, L.P.and 5 others13G/A0.20%65.9K shares−5.90 ppfrom 6.10%Below 5%Mar 31, 2026SEC
ANROAlto Neuroscience, Inc.May 15, 20264:11 PM ETPoint72 Asset Management, L.P.and 5 others13G/A3.70%1.17M shares−5.20 ppfrom 8.90%Below 5%Mar 31, 2026SEC
KRROKorro Bio, Inc.Mar 11, 20265:24 PM ETPoint72 Asset Management, L.P.and 5 others13G5.70%816.9K shares+2.80 ppfrom 2.90%Mar 10, 2026SEC
PRAXPraxis Precision Medicines, Inc.Feb 17, 20264:31 PM ETPoint72 Asset Management, L.P.and 5 others13G/A6.10%1.57M shares−3.50 ppfrom 9.60%Dec 31, 2025SEC
ANROAlto Neuroscience, Inc.Feb 17, 20264:30 PM ETPoint72 Asset Management, L.P.and 5 others13G/A8.90%2.82M shares+1.90 ppfrom 7.00%Dec 31, 2025SEC
KRROKorro Bio, Inc.Feb 17, 20264:29 PM ETPoint72 Asset Management, L.P.and 5 others13G/A2.90%276.8K shares−5.80 ppfrom 8.70%Below 5%Dec 31, 2025SEC
TSBXTurnstone Biologics Corp.Nov 14, 20254:14 PM ETPoint72 Asset Management, L.P.and 5 others13G/A0.00%0 shares–Below 5%Sep 30, 2025SEC
LENZLENZ Therapeutics, Inc.Nov 14, 20254:03 PM ETPoint72 Asset Management, L.P.and 5 others13G/A4.80%1.36M shares–Below 5%Sep 30, 2025SEC
PRAXPraxis Precision Medicines, Inc.Nov 14, 20254:00 PM ETPoint72 Asset Management, L.P.and 5 others13G/A9.60%2.07M shares+2.30 ppfrom 7.30%Sep 30, 2025SEC
PRAXPraxis Precision Medicines, Inc.Aug 14, 20255:01 PM ETPoint72 Asset Management, L.P.and 5 others13G/A7.30%1.53M shares+1.50 ppfrom 5.80%Jun 30, 2025SEC
KRROKorro Bio, Inc.Aug 14, 20254:53 PM ETPoint72 Asset Management, L.P.and 5 others13G/A8.70%816.9K shares–Jun 30, 2025SEC
PRAXPraxis Precision Medicines, Inc.May 15, 20254:35 PM ETPoint72 Asset Management, L.P.and 5 others13G/A5.80%1.21M shares−0.50 ppfrom 6.30%Mar 31, 2025SEC
ANROAlto Neuroscience, Inc.May 15, 20254:26 PM ETPoint72 Asset Management, L.P.and 5 others13G/A7.00%1.91M shares−1.80 ppfrom 8.80%Mar 31, 2025SEC
PRAXPraxis Precision Medicines, Inc.Feb 14, 20254:10 PM ETPoint72 Asset Management, L.P.and 5 others13G/A6.30%1.25M shares–Dec 31, 2024SEC
ANROAlto Neuroscience, Inc.Feb 14, 20254:05 PM ETPoint72 Asset Management, L.P.and 5 others13G/A8.80%2.36M shares–Dec 31, 2024SEC